Brief: Aligos Therapeutics Presents Positive Clinical Data At Hep-Dart 2023 From Phase 1 Studies In Hbv (Alg-000184) And Nash (Alg-055009)
07/12/2023 21:26
Dec 7 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS PRESENTS POSITIVE CLINICAL DATA AT
HEP-DART
2023 FROM PHASE 1 STUDIES IN HBV (ALG-000184) AND NASH
(ALG-055009)
Source text for Eikon: ID:nGNX8JMnsr
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue